Fananserin

5-HT2A antagonist. Also D4 antagonist CAS# 127625-29-0

Fananserin

Catalog No. BCC7440----Order now to get a substantial discount!

Product Name & Size Price Stock
Fananserin: 5mg $92 In Stock
Fananserin: 10mg Please Inquire In Stock
Fananserin: 20mg Please Inquire Please Inquire
Fananserin: 50mg Please Inquire Please Inquire
Fananserin: 100mg Please Inquire Please Inquire
Fananserin: 200mg Please Inquire Please Inquire
Fananserin: 500mg Please Inquire Please Inquire
Fananserin: 1000mg Please Inquire Please Inquire
Related Products
  • SP 600125

    Catalog No.:BCC2474
    CAS No.:129-56-6
  • JNK-IN-7

    Catalog No.:BCC1672
    CAS No.:1408064-71-0
  • CEP 1347

    Catalog No.:BCC7982
    CAS No.:156177-65-0
  • BI 78D3

    Catalog No.:BCC8089
    CAS No.:883065-90-5
  • CC-930

    Catalog No.:BCC1459
    CAS No.:899805-25-5
  • DB07268

    Catalog No.:BCC1519
    CAS No.:929007-72-7

Quality Control of Fananserin

Number of papers citing our products

Chemical structure

Fananserin

3D structure

Chemical Properties of Fananserin

Cas No. 127625-29-0 SDF Download SDF
PubChem ID 60785 Appearance Powder
Formula C23H24FN3O2S M.Wt 425.52
Type of Compound N/A Storage Desiccate at -20°C
Synonyms RP 62203
Solubility Soluble to 100 mM in DMSO
SMILES C1CN(CCN1CCCN2C3=CC=CC4=C3C(=CC=C4)S2(=O)=O)C5=CC=C(C=C5)F
Standard InChIKey VGIGHGMPMUCLIQ-UHFFFAOYSA-N
Standard InChI InChI=1S/C23H24FN3O2S/c24-19-8-10-20(11-9-19)26-16-14-25(15-17-26)12-3-13-27-21-6-1-4-18-5-2-7-22(23(18)21)30(27,28)29/h1-2,4-11H,3,12-17H2
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Fananserin

Description5-HT2A receptor antagonist that also displays high affinity at D4 receptors (Ki values are 0.26, 2.93, 25, 38, 70 and 726 nM for 5-HT2A, D4, H1, α1, 5-HT1A and D2 receptors respectively). Inhibits inositol phosphate formation evoked by 5-HT in vitro (IC50 = 7.76 nM) and antagonizes mescaline-induced head twitches in vivo.

Fananserin Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Fananserin Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Fananserin

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.3501 mL 11.7503 mL 23.5007 mL 47.0013 mL 58.7516 mL
5 mM 0.47 mL 2.3501 mL 4.7001 mL 9.4003 mL 11.7503 mL
10 mM 0.235 mL 1.175 mL 2.3501 mL 4.7001 mL 5.8752 mL
50 mM 0.047 mL 0.235 mL 0.47 mL 0.94 mL 1.175 mL
100 mM 0.0235 mL 0.1175 mL 0.235 mL 0.47 mL 0.5875 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
  • PF-3644022

    Catalog No.:BCC6136
    CAS No.:1276121-88-0
  • HS-173

    Catalog No.:BCC5363
    CAS No.:1276110-06-5
  • CNX1351

    Catalog No.:BCC6375
    CAS No.:1276105-89-5
  • VU 0360223

    Catalog No.:BCC6159
    CAS No.:1274859-33-4
  • Conantokin-T

    Catalog No.:BCC5977
    CAS No.:127476-26-0
  • Calystegine B1

    Catalog No.:BCN1882
    CAS No.:127414-86-2
  • Calystegine B2

    Catalog No.:BCN1879
    CAS No.:127414-85-1
  • Y-26763

    Catalog No.:BCC7253
    CAS No.:127408-31-5
  • Y-27152

    Catalog No.:BCC7254
    CAS No.:127408-30-4
  • Odoroside A

    Catalog No.:BCC8224
    CAS No.:12738-19-1
  • chroman 1

    Catalog No.:BCC1480
    CAS No.:1273579-40-0
  • Coclauril

    Catalog No.:BCN6150
    CAS No.:127350-68-9
New Products
 

References on Fananserin

A bridging study of fananserin in schizophrenic patients.[Pubmed:10513457]

Psychopharmacol Bull. 1998;34(4):811-8.

Fananserin is a potential antipsychotic compound with high affinity for both D4 and 5-HT2A receptors, and negligible affinity for D2 receptors. Because the tolerance for antipsychotic compounds often differs between schizophrenic patients and healthy subjects, this bridging study was designed to evaluate the tolerability of Fananserin, to define the slow titration maximum tolerated dose in the target population, and to identify the most rapid well-tolerated rate of titration for this compound. Three rates of titration regimens were examined in a total of 26 schizophrenic patients in a parallel group design, following a 3-day placebo washout period from previous antipsychotic medication. The slow rate of titration (reaching the maximum dose of 600 mg/day in 16 days with 100-mg increases every 3 days) was well tolerated, but a rapid titration schedule (reaching 600 mg/day in 8 days with 200-mg increases every 3 days) resulted in hypotension in 3 of 6 patients and termination of the group on Day 10. An intermediate rate of titration (reaching 600 mg/day in 10 days with 100-mg increases every 2 days) was then examined and was well tolerated, with transient episodes of mild hypotension reported in 2 of 10 patients. Thus, although hypotension was identified as the dose-limiting adverse event in this study, a reduction in the titration rate was effective in reducing the incidence and severity of this side effect. In this study, schizophrenic patients administered multiple doses of Fananserin tolerated doses 400 percent greater than the maximum tolerated single dose in healthy volunteers.

The naphtosultam derivative RP 62203 (fananserin) has high affinity for the dopamine D4 receptor.[Pubmed:8957240]

Eur J Pharmacol. 1996 Oct 24;314(1-2):229-33.

The dopamine D4 receptor is a potential target for novel antipsychotic drugs. Most available compounds with affinity for the dopamine D4 receptor also bind to dopamine D2 receptors. This report describe the affinity of the 5-HT2A receptor antagonist RP 62203 (Fananserin) for the human dopamine D4 receptor. Fananserin displaces [3H]spiperone binding to recombinant human dopamine D4 receptors with a Ki of 2.93 nM. This compares with an affinity (Ki) of 0.37 nM for the rat 5-HT2A receptor and of 726 mM for the rat dopamine D2 receptor. [3H]Fananserin can be used to label the recombinant dopamine D4 receptor expressed in Chinese hamster ovary cells with a KD of 0.725 nM. Fananserin is, thus, the first compound to be reported that distinguishes between dopamine D4 and D2 receptors.

Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia.[Pubmed:10080558]

Am J Psychiatry. 1999 Mar;156(3):419-25.

OBJECTIVE: The authors' objective was to assess the potential efficacy of Fananserin (RP62203), a potent antagonist at the D4 and serotonin2A (5-HT2A) receptors, on symptoms of schizophrenia. METHOD: A double-blind, placebo-controlled study was conducted in 97 patients. Doses of Fananserin reached 250 mg b.i.d. over 28 days, starting with an 8-day escalation. Most of the patients were men with paranoid schizophrenia; they were approximately 38 years old. The primary outcome measure was the total Positive and Negative Syndrome Scale score. The patients' mean score on the Positive and Negative Syndrome Scale at entry was 91.8 (SD=16.5). A low dropout rate was observed in both groups of patients (19 [30%] of those given Fananserin and nine [27%] of those given placebo). RESULTS: The total Positive and Negative Syndrome Scale score of the patients given Fananserin decreased at endpoint by a mean of 4.2 points (SD=15.4); the score of the patients given placebo decreased by 6.7 points (SD=19.6). No differences between treatments were found on secondary measures such as the Clinical Global Impression, Positive and Negative Syndrome Scale subscores or individual items, and Brief Psychiatric Rating Scale total score. The patients' extrapyramidal symptoms did not worsen during the trial, but the patients given Fananserin had an increase in akathisia. The safety profile was good in both groups of patients. CONCLUSIONS: The results of this study do not support the prediction that a selective D4 antagonist associated with strong 5-HT2A antagonism will exhibit an antipsychotic effect.

Pharmacological characterization of RP 62203, a novel 5-hydroxytryptamine 5-HT2 receptor antagonist.[Pubmed:1596688]

Br J Pharmacol. 1992 Jan;105(1):27-36.

1. RP 62203 (2-[3-(4-(4-fluorophenyl)-piperazinyl)propyl]naphto[1,8- ca]isothiazole-1,1-dioxide) is a novel naphtosultam derivative which shows very high affinity for 5-HT2 receptors in the rat cerebral cortex (Ki = 50.0 pM). 2. RP 62203 is relatively selective for this sub-type of 5-hydroxytryptamine (5-HT) receptor, having lower affinity for the 5-HT1A receptor and very low affinity for the 5-HT, receptor. RP 62203 displayed low to moderate affinity for alpha 1-adrenoceptors, dopamine D2 receptors and histamine H1 receptors. 3. In vivo binding experiments demonstrated that oral administration of low doses of RP 62203 led to a long-lasting (greater than 6 h) occupation of cortical 5-HT2 receptors (ID50 = 0.39 mgkg-1). 4. In cortical slices from the neonatal rat, RP 62203 potently inhibited inositol phosphate formation evoked by 5-HT, with an IC50 of 7.76 nM. 5. The activity of neurones in the raphe and their responses to microiontophoretically applied 5-HT were studied with extracellular recording electrodes in the anaesthetized rat. RP 62203 potently and dose-dependently blocked excitations evoked by 5-HT when administered at doses of 0.5-4.0 mg kg-1, i.p. In contrast, neither 5-HT-evoked depressions nor glutamate-evoked excitations of raphe neuronal firing were blocked by RP 62203 at doses as high as 8.0 mg kg-1, i.p. 6. Head twitches induced by 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) could be abolished by low doses of RP 62203 in mice (ED50 = 0.44 mg kg-1, p.o.) and in rats (ED50 = 1.54 p.o.). Similar results were obtained with mescaline and 5-hydroxytryptophan (5-HTP). 7. The potency of RP 62203 was compared with that of three other 5-HT2 receptor antagonists, ritanserin, ICI 169,369 and ICI 170,809. In all models, RP 62203 showed similar activity to ritanserin, whilst either ICI 169,369 or ICI 170,809 was several fold less active. 8. It is concluded that RP 62203 is a potent and selective antagonist at 5-HT2 receptors in the rodent central nervous system.

Naphthosultam derivatives: a new class of potent and selective 5-HT2 antagonists.[Pubmed:1908521]

J Med Chem. 1991 Aug;34(8):2477-83.

A series of 2-(aminoalkyl)naphth[1,8-cd]isothiazole 1,1-dioxides was synthesized and examined in various receptor binding tests. Most compounds demonstrated high affinity for the 5-HT2 receptor with moderate to high selectivity. A member of this series, compound 24 (RP 62203), displays high 5-HT2 receptor affinity (Ki = 0.26 nM), which is respectively more than 100 and 1000 times higher than its affinity for alpha 1 (Ki = 38 nM) and D2 (Ki greater than 1000 nM) receptors. This compound is a potent orally effective and long lasting 5-HT2 antagonist in the mescaline-induced head-twitches test in mice and rats.

Description

Fananserin (RP 62203) is an orally bioavailable, potent and selective 5-hydroxytryptamine2 (5-HT2) receptor antagonist, with a Ki of 0.37 nM for the rat 5-HT2A receptor. Fananserin also is a selective dopamine D4 receptor antagonist, with a Ki of 2.93 nM for the human dopamine D4 receptor.

Keywords:

Fananserin,127625-29-0,RP 62203,Natural Products,5-HT Receptor, buy Fananserin , Fananserin supplier , purchase Fananserin , Fananserin cost , Fananserin manufacturer , order Fananserin , high purity Fananserin

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: